Cholangiocarcinoma has quietly become one of the clearest proof points that precision oncology can change outcomes—not just theory, but real patients, real time. This talk will show how molecular profiling is reshaping how we diagnose, stratify, and treat this disease. From FGFR2 fusions and IDH1 mutations to emerging targets and mechanisms of resistance, we’ll walk […]